Monday, September 10, 2018
In the role of Head and Vice President of Oncology Research in Orion R&D, Johanna Ivaska will have all oncology discovery directly reporting to her. In addition, she will act as the Director of Orion Research Center for Biotechnology and Translational Research in Turku.
Ivaska is an internationally distinguished researcher specialising in the role of cellular changes in metastatic development in cancer. The innovative approach of her research will provide significant new data on the migration and traffic of cancer cells in tissue. Ivaska’s research is anticipated to lead to scientific breakthroughs in biomedicine, a very topical field of research today.
– I warmly welcome Johanna Ivaska to the Orion Oncology team. Johanna Ivaska has an outstanding career in science, and she is a widely recognised scholar internationally. In particular, she has an exceptional ability to be creative in her science, which skill is highly appreciated when developing novel drugs for serious diseases, such as cancer. Oncology is one of Orion’s main focus areas in the pharmaceutical Research and Development. Johanna Ivaska will have an important role in shaping the aims and structure of Orion Oncology. We feel privileged in hiring Johanna Ivaska, Professor Heikki Joensuu, R&D Global Head, Therapy Area Oncology in Orion says delightedly.
– I am excited to extend the co-operation with Orion Corporation. As a scientist, I have been passionately tackling biomedical research questions for over 20 years. Every new drug is based on curiosity driven fundamental research. However, drug development requires resources and know-how beyond academia. With my new appointment, I will have the opportunity to contribute to the other end of the process, the pharmacological therapy, Ivaska says.
Drug development and diagnostics have also been identified as the particular strengths of the research conducted at the University of Turku. However, further developing the findings in basic research for finished drugs often requires the resources of companies.
– The University of Turku has identified drug development and diagnostics as its particular strengths when it comes to research. While the fundamental discoveries that lead to new drugs are often made at universities, the further development of innovations always requires co-operation with private companies. For the University of Turku, Professor Ivaska’s partial transfer to Orion will be a model for developing co-operation with the private sector in the future, Kalervo Väänänen, Rector of the University of Turku states.
The co-operation between university research and drug industry has been developed especially within the BioCity Turku organisation.
– Founded nearly 30 years ago, BioCity Turku has always sought to systematically activate co-operation between researchers in the life sciences sector and the private sector. Professor Ivaska is one of Finland’s most influential oncology biologists and her work as a bridge builder between academia and private companies will promote the development of discoveries made in basic research into registered drugs, Jyrki Heino, Professor, Scientific Director of BioCity Turku says.
Ivaska Also Awarded with This Year’s Medix Prize
Twice during her career, Ivaska has received research funding awarded by European Research Council (ERC), which is among the most notable grants in the world and highly competed. Ivaska and her academic research team are also the recipients of many scientific awards including the most recent Medix Prize 2018 for the best scientific publication in medicine in Finland, and in 2017, the prestigious A. I. Virtanen Prize for internationally recognised excellence in research.
Most recently, Ivaska and her research group were awarded with Medix Prize of €20,000 for research exploring cell invasion and cancer. Medix Prize of the Minerva Foundation is a notable annual recognition for Finnish medical research of internationally high quality. In a way, it is the Finnish national championships of biomedicine.
In the research, a protein that prevents the spreading of cancer was found. The SHANK protein in question limits the activity of cancer cells and prevents them from invading tissues. Correspondingly, gene mutations in this protein weaken the effect of preventing invasion. The same article brought the group also the Elias Tillandz Prize of 2018.
The international, multidisciplinary research group in the BioCity lobby in Turku From left: PhD Maria Georgiadou, PhD Guillaume Jacquemet, PhD Ilkka Paatero, Doctoral Candidate Pranshu Sahgal, PhD Hussein Al-Akhrass, Academy Professor Johanna Ivaska, PhD Paulina Moreno-Layseca, PhD James Conway, Research Technician Jenni Siivonen, PhD Emilia Peuhu, Doctoral Candidate Johanna Lilja, PhD Hellyeh Hamidi, and Research Technician Petra Laasola. Photo: Martti Ahlstén.
The findings of the research group are significant for understanding both the spreading of cancer and the disorders of nerve cells related to autism.
– SHANK has been known to have a link with autism. A mutation in the SHANK protein or the missing of the protein predisposes the patient to severe autism, but the mechanism of how this happens has not been previously known. That was discovered in our research, too, Johanna Ivaska says.
However, there is no such link between cancer and autism that having autism leads to getting cancer or vice versa. The research group continues exploring the mechanisms of cancer and autism.
> The awarded article “SHANK proteins limit integrin activation by directly interacting with Rap1 and R-Ras” was published in the journal Nature Cell Biology
Original article was published on the University of Turku website 9/10/2018 10:55 AM
Friday, September 7, 2018
Professor John Eriksson was awarded with the title of Knight, First Class, of the Order of the White Rose of Finland
Professor John Eriksson was awarded with the title of Knight, First Class, of the Order of the White Rose of Finland by the President of the Republic of Finland, Sauli Niinistö, in conjunction with the celebration of the 100th Anniversary of Åbo Akademi University.
Friday, September 7, 2018
Professor Cecilia Sahlgren was awarded with the title of Knight, First Class, of the Order of the White Rose of Finland
Professor Cecilia Sahlgren was awarded with the title of Knight, First Class, of the Order of the White Rose of Finland by the President of the Republic of Finland, Sauli Niinistö, in conjunction with the celebration of the 100th Anniversary of Åbo Akademi University.
Tuesday, August 14, 2018
Laura Elo’s research presented on the pages of Tekniikan maailma
The research at our Centre gets lots of visibility. However, there are certain types of journals that we have difficulties reaching into, although they could provide positive visibility. One of these journals is clearly Tekniikan maailma (literally translated The World of Technology). To the best of our knowledge this journal for hard-core car and gadget enthusiasts has never published a word about TCB. However, now this shortcoming has been corrected, as Laura’s research was featured in article in the last July issue of the journal (No. 14/2018; text by Saga Wiklund, photo Hanna Oksanen/UTU Media Bank).
We got special permission from the journal to publish a free link to the article (in Finnish)
The beginning of article states “Better and more efficient cures through modeling – The aim of computational medicine is to improve diagnosis, prediction, and cures of complicated diseases” (the rest we hope that you can figure out with Google translate). Warm congratulations to Laura and her team for reaching over this rather rare treshold and for the other recent successes!
Friday, July 20, 2018
International collaboration between Finnish and U.S. researchers identify new rules for cancer therapies
More on University of Turku news page in Finnish.
Tuesday, June 26, 2018
Proteins are one of the major biomolecules that form the functional and structural entity of a living cell. Mass spectrometry-based quantitative proteomics can be used to determine the set of proteins expressed by a cell, tissue, or organism at a certain time.
The immune system defends the body against harmful pathogens and tumours, and also provides self-tolerance. T helper cells are major components of the adaptive system, and they play critical roles in controlling immune reactions.
During her postdoctoral study at the National Institutes of Health (NIH), USA, Dr. Zhi Chen started working on Th17 cells, a subset of helper T cells with an important role in autoimmune inflammation.
The label-free quantitative proteomics technology has been established at the Turku Centre for Biotechnology. Using this technology, Chen’s research team in collaboration with computational scientists from Aalto University and scientists from the University of Turku, Åbo Akademi University and the University of Maryland generated a resource that was used to identify over 4000 proteins expressed in Th17 and iTreg cells.
– We also combined analysis of proteome and gene expression data and discovered protein expression changes that were not associated with changes at the transcriptional level, says Chen.
– These identified proteins can potentially be targeted in immunotherapy, especially in disease conditions like cancer and autoimmunity, believes Chen.
The research is funded by grants from Academy of Finland and TEKES.
The study is published in the journal PLoS Biology.
Thursday, May 31, 2018
John Eriksson receives a grant from Academy of Finland for the project: “Integrating tissue homeostasis and regeneration – Cytoskeletal intermediate filaments as a signaling hub.
Intermediate filaments (IFs) have received significant attention due to the broad range of diseases they have been shown to be associated with. The IF-related diseases are associated with compromised tissue homeostasis as well as failing tissue regeneration and healing.
The overriding hypothesis of the proposal is that IF-mediated signaling maintains tissue integrity and homeostasis. The proposed novel concept is that tissue-integrating signaling is linked to a major cytoskeletal system, which in turn can take cues from other signaling pathways, cell shape, migration, and biomechanics. The project aims to uncover how signal processing is managed in concert with tissue organization and biomechanics.
The molecular knowledge gained by this study provides great potential for diagnostic, prognostic, and therapeutic approaches to tackle several relevant disease conditions, including regular and chronic wounds, internal injuries, regeneration or degeneration, different fibrotic diseases, and cancer.
The project links to the strong community of cytoskeletal and adhesion research in Turku and both gains strength from and strengthens this community.
Monday, May 28, 2018
Adjunct Professor Laura Elo received the L’Oréal-UNESCO For Women in Science Award Finland 2018. Laura Elo works as Research Director in Bioinformatics and Group Leader in Computational Biomedicine at Turku Centre for Biotechnology.
The international L’Oreal -UNESCO For Women in Science Award was initiated in 1998 to promote equality in science. In Finland, the Award was launched in 2006.
Thursday, May 17, 2018
Lea Sistonen, who is Professor of Cellular and Molecular Biology at Åbo Akademi University and an Affiliated Group Leader at Centre for Biotechnology, has been elected as a new member of the prestigious life science organization EMBO (European Molecular Biology Organization). As defined by the organization, election to EMBO Membership is recognition of research excellence and the outstanding achievements made by a life scientist.
She joins the other two previously elected EMBO members from Turku, Professors Sirpa Jalkanen and Johanna Ivaska.
Wednesday, May 9, 2018
International Collaboration between U.S. and Finnish Researchers Identifies New Approach for Treating Neuropathic Pain
Neuropathic pain is the chronic, pathological pain that continues even when the cause of pain is removed. Causes include damage to nerve cells and medicines used to treat cancer. A collaboration between research groups from Indiana University in Bloomington, USA and Turku Centre for Biotechnology in Finland has discovered an experimental molecule that appears to interrupt the signaling cascades in the body required for multiple forms of neuropathic pain.
The adaptor protein NOS1AP in a microscopic image.
Neuropathic pain is extremely common, affecting up to 5-10% of the population globally, and no cures or effective treatments are currently available. Moreover, chemotherapy-induced pain can be so extreme that it causes some patients with cancer to discontinue treatment and greatly impairs quality of life in survivors.
Prior to this study, researchers were aware that pathological pain is triggered by a biological pathway that is activated by binding of the excitatory transmitter glutamate to receptors called NMDARs. This process then triggers activation of an enzyme neuronal nitric oxide synthase (nNOS) that generates nitric oxide gas that plays a role in aberrant pain sensation. However, experimental drugs designed to block either the NMDAR receptor or the nNOS enzyme can cause intolerable side effects, such as memory impairment and motor dysfunction.
Now, researchers from Indiana University in Bloomington, USA and the Turku Centre for Biotechnology in Finland have demonstrated that an experimental molecule reduces neuropathic pain in rodents resulting from either nerve damage or a common chemotherapy drug.
The team in Finland was able to design the molecule after discovering that a protein, NOS1AP, that is downstream of nNOS, triggers several biological pathways that are associated with abnormal glutamate signaling, including neuropathic pain.
The Indiana University group demonstrated that an experimental molecule designed by the Turku group to prevent nNOS signalling to NOS1AP reduced two forms of neuropathic pain in rodents. These forms of pain develop as result of either chemotherapeutic agent paclitaxel or nerve damage.
The treatment also disrupted markers of nociceptive signaling in the spinal cord when the test drug was injected at that site into mice. Importantly, the NOS1AP inhibitor did not cause typical motor side effects observed with previous experimental molecules that directly target NMDARs.
– Importantly, the chemical that prevents this signalling did not cause the negative side effects observed in previous experiments. Our studies suggest that the nNOS-NOS1AP interaction site is a previously unrecognized target for pain therapies”, says Professor Andrea Hohmann from the Indiana University in Bloomington.
The results suggest that the protein NOS1AP might be a valuable novel target in the development of more effective medicines to treat neuropathic pain.
– NOS1AP should be studied in more detail to find the best way to prevent this protein from contributing to chronic pain, said Senior Researcher Michael Courtney from the University of Turku.
This research is funded by the National Institutes of Health’s National Cancer Institute (grantome.com/grant/NIH/R01-CA200417) held jointly by Andrea Hohmann at Indiana University and Michael Courtney in Turku.